Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Ann Surg. 2022 Mar 1;275(3):e562–e567. doi: 10.1097/SLA.0000000000004150

Table 1.

Background characteristics of study patients stratified receipt of adjuvant chemotherapy. Categorical variables are expressed as count (percentage) and continuous variables as median (interquartile range)

Variable No Adjuvant
Chemotherapy
(n=811) (%)
Adjuvant
Chemotherapy
(n=922) (%)
p-value
Age (median [IQR]) 67(60-75) 62(55-70) <0.001
Sex (female) 115(14) 103(11) 0.07
Race/ethnicity 0.63
White 771(96) 888(97)
Black 20(3) 17(2)
Other 11(1) 11(1)
Year of diagnosis 2007(2006-2010) 2008(2005-2010) 0.93
Charlson-Deyo score 0.002
0 533(66) 657(71)
1 211(26) 224(24)
≥2 67(8) 41(4)
Insurance <0.001
Private 301(38) 482(53)
Government 484(61) 417(46)
None 12(1) 10(1)
Academic center 454(57) 404(44) <0.001
Pathologic T status 0.24
T1 178(22) 173(19)
T2 172(21) 182(20)
T3 446(55) 549(60)
T4 15(2) 18(2)
Tumor size (mm) 38(25-50) 38(25-55) 0.49
Grade 0.923
Low 24(3) 29(3)
Moderate 286(37) 323(36)
High 462(60) 542(61)
Annualized center volume 6(3-16) 4(2-10) <0.001
Lymph node ratio (%) 19(8-40) 21(10-40) 0.10
Number of nodes examined 14(9-20) 15(10-21) 0.12
Number of nodes positive 2(1-4) 3(1-5) 0.001
Adjuvant radiation 80(10) 650(71) <0.001
Number of radiation treatments 28(25-30) 26(25-28) N/A
Radiation dose (Gy) 50.4(45.0-50.4) 45.0(45.0-50.4) N/A
Unplanned 30-day readmission 70(9) 50(5) 0.01
Postoperative length of stay 11(8-18) 9(7-13) <0.001